Delandistrogene moxeparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Delandistrogene moxeparvovec Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
11
Registered trials
26
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Delandistrogene moxeparvovec can convert its AAV based gene therapy profile and micro-dystrophin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Delandistrogene moxeparvovec (query alias: delandistrogene moxeparvovec) |
|---|---|
| Modality / target | AAV based gene therapy; micro-dystrophin; micro-dystrophin stimulants |
| Highest global status | Approved |
| Originator | Nationwide Children's Hospital |
| Active developers | Sarepta Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., Roche Holding AG |
The MCP disease footprint includes Muscular Dystrophy, Duchenne. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07542314 | Phase 4 | Not yet recruiting | 20 | Cohort 1: Number of Participants with ALI |
| NCT06241950 | Phase 1 | Terminated | 5 | Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content |
| NCT06597656 | Phase 1 | Terminated | 3 | Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression Adjusted by Muscle Content Biopsied Muscle as Measured by Western Blot |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Lowering pre-existing immunity to adeno-associated virus-based gene therapy: Pre treatment with imlifidase or plasmapheresis prior to administration of delandistrogene moxeparvovec in Duchenne muscular dystrophy ‑
Phase 1; n=8; evaluation: Positive. Reported fields: Micro-dystrophin Expression(Week 12) = 21.5 % ( 0.96 - 42.03); Micro-dystrophin Expression(Week 12) = 1.72 % ( 1.46 - 2.11)
Family experience data with delandistrogene moxeparvovec gene therapy treatment for Duchenne muscular dystrophy.
Not Applicable; n=31; evaluation: Positive. Reported fields: Improvement in at least one of the most impactful symptoms = 96.0 %
LB: Pooled Safety Analysis from Phase 1 to Phase 3 Clinical Trials of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy
; n=236; evaluation: Positive. Reported fields: TR-TEAE = Most frequently reported (≥15% of patients) TR-TEAEs were vomiting (58.5%), nausea (36.0%), decreased appetite (28.8%), glutamate dehydrogenase increased (20.3%), and gamma-glutamyl transferase increased (15.3%).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Delandistrogene moxeparvovec addresses Muscular Dystrophy, Duchenne. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—AAV based gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-01-05 | Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate | Not disclosed | Financial terms not disclosed |
| 2021-12-16 | Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy | Phase 3 | Financial terms not disclosed |
| 2020-07-02 | Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications | Phase 2 | US$10.0M upfront; US$397.5M milestones; US$407.5M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
